Preclinical Comparison of Two CD3xB7H4 bsAbs with Divergent CD3 Affinities for the Treatment of Solid Tumors
Time: 1:40 pm
day: Day Two
Details:
- Discussing the impact of CD3 affinity on the trade-off between efficacy and safety in preclinical solid tumor models
- Exploring how translational insights around antigen expression levels, bystander activity, and tolerability in tumor models may carry over to chronic inflammatory indications
- Reflection on how learnings from immuno-oncology TCE design may inform safer and more effective strategies in autoimmune disease settings
